Update on chronic hepatitis C in hemophiliacs.

Abstract:

BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients affected by hereditary bleeding disorders and treated with non-virus inactivated clotting factor concentrates during the 1970s. INFORMATION SOURCES:In this review, we briefly report the present knowledge about HCV infection in hemophilic patients. The natural course of hepatitis C virus infection in hemophiliacs is described, by analyzing the prevalence of HCV infection, the genotype distribution and the risk factors involved in the progression of chronic hepatitis into severe liver disease such as cirrhosis, liver decompensation and hepatocellular carcinoma. STATE OF THE ART AND PERSPECTIVES:We focus on the most important advances in the treatment of hepatitis C in hemophiliacs.

journal_name

Haematologica

journal_title

Haematologica

authors

Franchini M,Capra F,Tagliaferri A,Rossetti G,De Gironcoli M,Rocca P,Aprili G,Gandini G

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

542-9

issue

5

eissn

0390-6078

issn

1592-8721

journal_volume

87

pub_type

杂志文章,评审
  • Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma.

    abstract:BACKGROUND AND OBJECTIVES:Pathogen-derived molecules are danger signals and are able to activate innate immunity that in turn controls and regulates generation of adaptive immune responses. Mycobacterium tuberculosis heat shock protein 70 (myc HSP70) has been shown to exert a potent adjuvant effect in vaccination again...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Liso A,Benedetti R,Fagioli M,Mariano A,Falini B

    更新日期:2005-01-01 00:00:00

  • Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.

    abstract::Eleven patients with advanced APL were treated with ATO (0.15 mg/Kg daily). Eight (73%) achieved molecular CR, but 5 relapsed, 1 died in molecular CR, 1 was lost to follow-up and 1 is still alive in CR after allogeneic transplantation. We suggest that ATO may be effective also in advanced APL, but given the short CR, ...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Carmosino I,Latagliata R,Avvisati G,Breccia M,Finolezzi E,Lo Coco F,Petti MC

    更新日期:2004-05-01 00:00:00

  • Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

    abstract:BACKGROUND AND OBJECTIVES:The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone. DESIGN AND METHODS:In two previously reported, open-label, multicenter phase 2 studies, bortezomib 1.0 or 1.3 mg/m2 was ...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Jagannath S,Richardson PG,Barlogie B,Berenson JR,Singhal S,Irwin D,Srkalovic G,Schenkein DP,Esseltine DL,Anderson KC,SUMMIT\/CREST Investigators.

    更新日期:2006-07-01 00:00:00

  • Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis.

    abstract::Differentiation of erythroblasts to mature red blood cells involves dynamic changes of the membrane and cytoskeleton networks that are not fully characterized. Using a mouse fetal liver erythroblast culture system and a targeted shRNA functional screening strategy, we identified a critical role of pleckstrin-2 in acti...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.105809

    authors: Zhao B,Keerthivasan G,Mei Y,Yang J,McElherne J,Wong P,Doench JG,Feng G,Root DE,Ji P

    更新日期:2014-07-01 00:00:00

  • Quantification of D-dimer using a new fully automated assay: its application for the diagnosis of deep vein thrombosis.

    abstract:BACKGROUND AND OBJECTIVE:A D-dimer assay can be helpful to rule out thromboembolism provided it is sensitive, reliable, fast and easy to perform. Tests based on the ELISA methodology have a high diagnostic sensitivity, and are therefore adequate for excluding deep venous thrombosis (DVT). The drawbacks are their long a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Villa P,Ferrando F,Serra J,Faus H,Mira Y,Vayá A,Aznar J

    更新日期:2000-05-01 00:00:00

  • Cell cycle kinetic changes induced by interleukin-3 and interleukin-6 during ex vivo expansion of mobilized peripheral blood CD34 cells.

    abstract::The long-term repopulating capacity of mobilized peripheral blood (MPB) CD34+ cells can be abrogated during ex vivo expansion due to cell-cycle related changes. In this study, we traced cell cycle kinetic and quiescent status of CD34+ cells during ex vivo expansion with exogenous cytokines. The addition of interleukin...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Sanchez-Garcia J,Torres A,Herrera C,Alvarez MA

    更新日期:2006-01-01 00:00:00

  • NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms.

    abstract:BACKGROUND AND OBJECTIVES:NAD(P)H:quinone oxidoreductase 1 (NQO1) is an enzyme that protects cells against mutagenicity from free radicals and toxic oxygen metabolites. The gene coding for NQO1 is subject to a genetic polymorphism at nucleotide position 609 (C-->T) of the human NQO1 cDNA. Heterozygous individuals (C/T)...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Kracht T,Schrappe M,Strehl S,Reiter A,Elsner HA,Trka J,Cario G,Viehmann S,Harbott J,Borkhardt A,Metzler M,Langer T,Repp R,Marschalek R,Welte K,Haas OA,Stanulla M

    更新日期:2004-12-01 00:00:00

  • Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.

    abstract:BACKGROUND AND OBJECTIVE:A prospective study to evaluate the role of fludarabine alone or in combination with idarubicin in untreated patients with mantle cell lymphoma (MCL). DESIGN AND METHODS:Twenty-nine untreated patients with mantle cell lymphoma were stochastically treated with intravenous fludarabine at a dose ...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Zinzani PL,Magagnoli M,Moretti L,Battista R,Ronconi F,De Renzo A,Zaccaria A,Gentilini P,Guardigni L,Gherlinzoni F,Cellini C,Fattori PP,Bendandi M,Bocchia M,Aitini E,Tura S

    更新日期:1999-11-01 00:00:00

  • Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

    abstract::We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.238675

    authors: Svoboda J,Bair SM,Landsburg DJ,Nasta SD,Nagle SJ,Barta SK,Khan N,Filicko-O'Hara J,Gaballa S,Strelec L,Chong E,Mitnick S,Waite TS,King C,Ballard H,Youngman M,Gerson J,Plastaras JP,Maity A,Bogusz AM,Hung SS,Nakamu

    更新日期:2020-05-15 00:00:00

  • SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

    abstract::Mastocytosis is a rare and chronic disease with phenotypes ranging from indolent to severe. Prognosis for this disease is variable and very few biomarkers to predict disease evolution or outcome are currently known. We have performed comprehensive screening in our large cohort of mastocytosis patients for mutations pr...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2013.095133

    authors: Hanssens K,Brenet F,Agopian J,Georgin-Lavialle S,Damaj G,Cabaret L,Chandesris MO,de Sepulveda P,Hermine O,Dubreuil P,Soucie E

    更新日期:2014-05-01 00:00:00

  • Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

    abstract::Chronic autoimmune or pathogen-induced immune reactions resulting in lymphoid neogenesis are associated with development of malignant lymphomas, mostly extranodal marginal zone B-cell lymphomas (MZBCLs). In this review we address (i) chemokines and adhesion molecules involved in lymphoid neogenesis; (ii) the autoimmun...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.2009.005983

    authors: Bende RJ,van Maldegem F,van Noesel CJ

    更新日期:2009-08-01 00:00:00

  • Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

    abstract:BACKGROUND:Many different techniques have been designed for the quantification of JAK2V617F allelic burden, sometimes producing discrepant results. DESIGN AND METHODS:JAK2V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specif...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.13486

    authors: Lippert E,Girodon F,Hammond E,Jelinek J,Reading NS,Fehse B,Hanlon K,Hermans M,Richard C,Swierczek S,Ugo V,Carillo S,Harrivel V,Marzac C,Pietra D,Sobas M,Mounier M,Migeon M,Ellard S,Kröger N,Herrmann R,Prchal JT

    更新日期:2009-01-01 00:00:00

  • Fibrinogen survival and fibrinopeptide A in acute leukemia.

    abstract::BACKGROUND. Hypofibrinogenemia and increased fibrin(ogen) degradation products in acute leukemia have been attributed to intravascular thrombin generation triggered by leukemic cells. However, the strict relationship between fibrinogen catabolism and turnover of fibrinopeptide A (FPA), which is a sensitive and specifi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Castaman G,Galloni E,Dri AV,Rodeghiero F

    更新日期:1993-11-01 00:00:00

  • The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.

    abstract::We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61)...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Knop S,Straka C,Haen M,Schwedes R,Hebart H,Einsele H

    更新日期:2005-09-01 00:00:00

  • Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.

    abstract::Phase I/II studies of gemtuzumab ozogamicin (GO) in pediatric refractory/relapsed acute myeloid leukemia (AML) have been reported. We present the cases of two children with relapsed AML who were treated with GO plus cytarabine, leading to a decrease of minimal residual disease down to levels not previously obtained. T...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Brethon B,Auvrignon A,Cayuela JM,Lapillonne H,Leverger G,Baruchel A

    更新日期:2006-03-01 00:00:00

  • Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency.

    abstract::To date, few mutations associated with a dominant quantitative deficiency of von Willebrand factor (VWF) and a high penetrance have been reported. This phenotype was confirmed in seven unrelated families of several patients diagnosed with von Willebrand's disease out of 70 who requested genetic studies of the VWF gene...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Casaña P,Cabrera N,Haya S,Cid AR,Aznar JA

    更新日期:2006-08-01 00:00:00

  • Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.

    abstract::In childhood B-cell precursor acute lymphoblastic leukemia, cytogenetics is important in diagnosis and as an indicator of response to therapy, thus playing a key role in risk stratification of patients for treatment. Little is known of the relationship between different cytogenetic subtypes in B-cell precursor acute l...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3324/haematol.2013.085175

    authors: Schwab CJ,Chilton L,Morrison H,Jones L,Al-Shehhi H,Erhorn A,Russell LJ,Moorman AV,Harrison CJ

    更新日期:2013-07-01 00:00:00

  • Acute nonlymphocytic leukemia in the elderly: results of a retrospective study.

    abstract::Seventy-four patients over 60 years of age with new cases of ANLL diagnosed between January, 1980 and December, 1986 were retrospectively evaluated. Twenty-nine (median age 63, range 60-70) received aggressive induction polychemotherapy: 15 achieved CR (52%), 10 were resistant (34.5%) and 4 died during induction (13.5...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Latagliata R,Sgadari C,Pisani F,Falconi M,Spadea A,Vegna ML,Petti MC

    更新日期:1989-03-01 00:00:00

  • Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.

    abstract:BACKGROUND AND OBJECTIVES:The role of hematopoietic chimerism after allogeneic stem cell transplantation (SCT) for acute leukemia remains controversial. We studied the relationship between hematopoietic chimerism and several prognostic variables on the outcome of SCT in patients with acute leukemia. DESIGN AND METHODS...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Barrios M,Jiménez-Velasco A,Román-Gómez J,Madrigal ME,Castillejo JA,Torres A,Heiniger A

    更新日期:2003-07-01 00:00:00

  • Neurological disorders in essential thrombocythemia.

    abstract::Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy. Among 37 consecutive patients with essential thrombocythemia, 11 presented with neurological symptoms. Among them 4 had thrombotic events, 7...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2011.050005

    authors: Billot S,Kouroupi EG,Le Guilloux J,Cassinat B,Jardin C,Laperche T,Fenaux P,Carpentier AF,Kiladjian JJ

    更新日期:2011-12-01 00:00:00

  • Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

    abstract::Immunoparesis or suppression of polyclonal immunoglobulins is a very common condition in newly diagnosed myeloma patients. However, the recovery of polyclonal immunoglobulins in the setting of immune reconstitution after autologous stem cell transplantation and its effect on outcome has not yet been explored. We condu...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2016.158345

    authors: González-Calle V,Cerdá S,Labrador J,Sobejano E,González-Mena B,Aguilera C,Ocio EM,Vidriales MB,Puig N,Gutiérrez NC,García-Sanz R,Alonso JM,López R,Aguilar C,de Coca AG,Hernández R,Hernández JM,Escalante F,Mateos MV

    更新日期:2017-05-01 00:00:00

  • Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.

    abstract:BACKGROUND AND OBJECTIVES:Somatic hypermutation of the BCL6 gene and its expression in lymphoma represent specific markers for B-cell transit through the germinal center. Thus, analysis of BCL6 may aid in clarifying the relationship between primary mediastinal B-cell lymphoma (PMBL) and other non-thymic diffuse large c...

    journal_title:Haematologica

    pub_type: 杂志文章,meta分析

    doi:

    authors: Malpeli G,Barbi S,Moore PS,Scardoni M,Chilosi M,Scarpa A,Menestrina F

    更新日期:2004-09-01 00:00:00

  • A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy.

    abstract:BACKGROUND AND OBJECTIVES:Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative agent with unique erythropoietin receptor activity and a prolonged half-life, which has the potential for administration at extended dosing intervals. The objectives of this dose-finding study were to evaluate the hemoglo...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3324/haematol.10730

    authors: Dmoszynska A,Kloczko J,Rokicka M,Hellmann A,Spicka I,Eid JE

    更新日期:2007-04-01 00:00:00

  • Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation.

    abstract::Autoimmune lymphoproliferative syndrome is a rare genetic disorder characterized by defective FAS-mediated apoptosis, autoimmune disease, accumulation of mature T-cell receptor alpha/beta positive, CD4 and CD8 double-negative T cells and increased risk of lymphoma. Despite frequent hematologic abnormalities, literatur...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2015.138081

    authors: Xie Y,Pittaluga S,Price S,Raffeld M,Hahn J,Jaffe ES,Rao VK,Maric I

    更新日期:2017-02-01 00:00:00

  • Clonal stability of initial leukemia in a child with central nervous system relapse 7.4 years after bone marrow relapse of common acute lymphoblastic leukemic.

    abstract::Second central nervous system (CNS) relapses represent about 7.3% of subsequent recurrences of childhood acute lymphoblastic leukemia (ALL). In most children these subsequent CNS relapses occur during the first 18 months after diagnosis of the first relapse (mean 1.42 +/- 0.73 years). We present a patient who suffered...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Eckert C,Einsiedel HG,Hartmann R,von Stackelberg A,Völpel S,Guggemos A,Hanzsch N,Kawan L,Seeger K,Henze G

    更新日期:2004-07-01 00:00:00

  • Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.

    abstract:BACKGROUND:The nucleoside analogue fludarabine is used in the treatment of chronic lymphocytic leukemia. It triggers p53-mediated apoptosis, although the mutational status of p53 does not fully account for heterogeneity in responsiveness to treatment. The aim of this study was to identify new genes implicated in fludar...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13186

    authors: López-Guerra M,Trigueros-Motos L,Molina-Arcas M,Villamor N,Casado FJ,Montserrat E,Campo E,Colomer D,Pastor-Anglada M

    更新日期:2008-12-01 00:00:00

  • Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

    abstract:BACKGROUND:Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant protein that stimulates activated protein C and tissue factor pathway inhibitor. Hereditary type I protein S deficiency (low total and low free protein S) is a well-established risk factor for venous thrombosis, whereas t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.021923

    authors: Castoldi E,Maurissen LF,Tormene D,Spiezia L,Gavasso S,Radu C,Hackeng TM,Rosing J,Simioni P

    更新日期:2010-09-01 00:00:00

  • B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

    abstract:BACKGROUND AND OBJECTIVES:Rituximab reacts specifically with the CD20 antigen and induces B-cell depletion. This could interfere with the production of autoantibodies in some immune diseases. The objective of this study was to assess the effects of rituximab in autoimmune hemolytic anemia and thrombocytopenia. DESIGN ...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Zaja F,Iacona I,Masolini P,Russo D,Sperotto A,Prosdocimo S,Patriarca F,de Vita S,Regazzi M,Baccarani M,Fanin R

    更新日期:2002-02-01 00:00:00

  • Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.

    abstract::Interactions between chronic lymphocytic leukemia (CLL) B cells and the bone marrow (BM) microenvironment play a major function in the physiopathology of CLL. Extracellular vesicles (EVs), which are composed of exosomes and microparticles, play an important role in cell communication. However, little is known about th...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.163337

    authors: Crompot E,Van Damme M,Pieters K,Vermeersch M,Perez-Morga D,Mineur P,Maerevoet M,Meuleman N,Bron D,Lagneaux L,Stamatopoulos B

    更新日期:2017-09-01 00:00:00

  • L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.

    abstract:BACKGROUND AND OBJECTIVE:Altered adhesive interaction between bone marrow (BM) stroma and progenitors in chronic myeloid leukemia (CML) may be in part caused by abnormal expression of cell adhesion molecules (CAMs) on malignant progenitor cells. Treatment of CML with interferon-a (IFN-a) re-establishes normal hemopoies...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Martín-Henao GA,Quiroga R,Sureda A,González JR,Moreno V,García J

    更新日期:2000-02-01 00:00:00